Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Generation of Induced Pluripotent Stem Cells Derived Tolerogenic Dendritic Cells and Their Immunosuppressive Properties.

ABSTRACT: Background: Dendritic cells (DCs), the primary antigen-presenting cells, regulate immune priming. DCs with a semi-mature phenotype and tolerogenic properties, termed tolerogenic DCs (tolDCs), are promising candidates for cell therapy to induce immune tolerance. Induced pluripotent stem cells (iPSCs) can provide an unlimited source of DCs, and in mice, tolDCs can be generated from bone marrow cells by adding agents such as minocycline and dexamethasone during DC differentiation. On this basis, we aimed to establish a protocol for generating tolDCs from iPSCs. Methods: We modified an existing iPSC-to-DC induction protocol by adding minocycline and dexamethasone. Then, we assessed whether the resulting cells exhibited tolDC characteristics through comparison of iPSC-derived DCs (iPS-DCs) and iPSC-derived tolDCs (iPS-tolDCs). Results: We established a method for generating iPS-tolDCs from iPSCs. Flow cytometric analysis revealed reduced expression of co-stimulatory molecules and the maturation marker in iPS-tolDCs compared with iPS-DCs. In co-culture experiments, CD4⁺CD45RA⁺ T cells isolated from PBMCs of healthy donors or patients with autoimmune diseases showed reduced proliferation when cultured with iPS-tolDCs compared with iPS-DCs. Gene expression profiles of iPS-tolDCs differed from those of iPS-DCs. Conclusion: We developed a protocol for producing tolDCs from iPSCs and demonstrated their tolerogenic phenotype and immunosuppressive effects on T cells. These findings indicate that iPS-tolDCs are a promising candidate for cellular immunotherapy and warrant further investigation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE307178 | GEO | 2026/03/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_1 array]

Project description:Glucocorticoids (GCs) exert potent anti-inflammatory effects in immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. Tolerogenic DCs (tolDCs) have emerged as a potential treatment for different inflammatory diseases. To date, the underlying cell type-specific regulatory mechanisms orchestrating GC-mediated acquisition of immunosuppressive properties remain poorly understood. In this study, we investigated the transcriptomic and epigenomic remodeling associated with differentiation to DCs in the presence of GCs. Our analysis demonstrates a major role of MAFB in this process, in synergy with GR. Both GR and MAFB interact with methylcytosine dioxygenase TET2 and bind to genomic loci that undergo specific demethylation in tolDCs. We also show that the role of MAFB is more extensive, binding to thousands of genomic loci in tolDCs. Finally, MAFB knockdown erases the tolerogenic properties of tolDCs and reverts the specific DNA demethylation and gene upregulation. The preeminent role of MAFB is also demonstrated in vivo for myeloid cells from synovium in rheumatoid arthritis following GC treatment. These results support that, once directly activated by GR, MAFB takes over the main roles to orchestrate the epigenomic and transcriptomic remodelling that define the tolerogenic phenotype.

2021-11-11 | GSE180535 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [expression array]

2021-11-11 | GSE180533 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [RNA_SEQ]

2021-11-11 | GSE180540 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [CHIP_SEQ]

2021-11-11 | GSE180539 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_2 array]

2021-11-11 | GSE180537 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

Project description:Glucocorticoids (GCs) exert potent anti-inflammatory effects in innate immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. Tolerogenic DCs (tolDCs) have emerged as a potential treatment for different inflammatory diseases. To date, the underlying cell type-specific regulatory mechanisms orchestrating GC-mediated acquisition of immunosuppressive properties remain poorly understood. In this study, we investigated the transcriptomic and epigenomic remodeling associated with differentiation to DCs in the presence of GCs. Our analysis demonstrates a major role of MAFB in this process, in synergy with GR. Both GR and MAFB interact with methylcytosine dioxygenase TET2 and bind to genomic loci that undergo specific demethylation in tolDCs. We also show that the role of MAFB is more extensive, binding to thousands of genomic loci in tolDCs. Finally, MAFB knockdown erases the tolerogenic properties of tolDCs and reverts the specific DNA demethylation and gene upregulation. The preeminent role of MAFB is also demonstrated in vivo for myeloid cells from synovium in rheumatoid arthritis following GC treatment. These results support that, once directly activated by GR, MAFB takes over the main roles to orchestrate the epigenomic and transcriptomic remodelling that define the tolerogenic phenotype.

2021-11-11 | GSE181082 | GEO

Expression data (HG-U133 Plus 2.0) from human monocyte-derived cell types (TolDC, M-MDSC, MoDC)

Project description:A better understanding of the mechanisms that induce and drive human suppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tolerogenic dendritic cells (TolDCs), stimulates therapeutic approaches that intent to restore the immune balance in patients. Here, we compared gene profiles of in vitro generated M-MDSCs to TolDCs in the context of monocytes and monocyte-derived DCs (MoDCs).

2021-09-20 | GSE182528 | GEO

Tolerogenic dendritic cells protect against acute kidney injury

Project description:We use tolDCs from syngeneic (C57BL6) and allogeneic (BALB/c) mice to show potent renoprotective abilities in a ischemia reperfusion AKI model. Dendritic cells were derived from mice bone marrow and cultured for 7 days with GM-CSF and IL-4. Tolerogenic DCs were cultured in the same DC media but with the addition of VitD3 and IL10. LPS was added on day 6 and cells harvested for use or analysis on day 7.

2024-11-25 | E-MTAB-14618 | biostudies-arrayexpress

Tolerogenic dendritic cells protect against acute kidney injury

2023-07-01 | GSE205322 | GEO

Small molecules facilitate rapid and synchronous iPSC generation

Project description:The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) upon overexpression of OCT4, KLF4, SOX2 and c-MYC (OKSM) provides a powerful system to interrogate basic mechanisms of cell fate change. However, iPSC formation with standard methods is typically protracted and inefficient, resulting in heterogeneous cell populations. We show that exposure of OKSM-expressing cells to both ascorbic acid and a GSK3-β inhibitor (AGi) facilitates more synchronous and rapid iPSC formation from several mouse cell types. AGi treatment restored the ability of refractory cell populations to yield iPSC colonies, and it attenuated the activation of developmental regulators commonly observed during the reprogramming process. Moreover, AGi supplementation gave rise to chimera-competent iPSCs after as little as 48 h of OKSM expression. Our results offer a simple modification to the reprogramming protocol, facilitating iPSC induction at unparalleled efficiencies and enabling dissection of the underlying mechanisms in more homogeneous cell populations. 18 samples were analyzed in total, samples represent bulk cultures of reprogrammable-MEFs (Rep-MEFs) that express OKSM and were supplemented with ascorbic acid and GSK3i during iPS cell induction. Control samples represent similar bulk cultures of reprogrammable-MEFs that express OKSM but were not supplemented with ascorbic acid and GSK3i during iPS cell induction. GMP-iPSCs were generated using 48 hours of OKSM+AGi induction. Fibroblast-iPSCs were generated using 96 hours of OKSM+AGi induction.

2014-09-23 | E-GEOD-57774 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data